Brainstorm Cell Therapeutics | BCLI - Ebit

Stock Price
0.85
Daily Change
-0.02 -1.73%
Monthly
-5.56%
Yearly
6.92%
Q2 Forecast
0.90

Brainstorm Cell Therapeutics reported $-2.05M in EBIT for its fiscal quarter ending in September of 2025.





Ebit Change Date
Alterity Therapeutics Limited AUD -8.07M 302.4K Dec/2025
Biogen USD 659.6M 157M Sep/2025
Brainstorm Cell Therapeutics USD -2.05M 526K Sep/2025
Cipla INR 9.77B 6.21B Dec/2025
Clal Biotechnology ILS -5.44M 3.76M Dec/2022
Compugen USD 56.04M 63.94M Dec/2025
CSL USD 2.64B 116M Dec/2025
Cytokinetics USD -178.37M 11.61M Dec/2025
Gilead Sciences USD 2.96B 551M Dec/2025
Grifols EUR 320.55M 91.01M Dec/2025
Halozyme Therapeutics USD -88.41M 306.33M Dec/2025
Mesoblast USD -27.75M 14.36M Dec/2025